Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,709
Out of 5,115 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.12 | +2,132.14% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.73 | +266.30% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $10.51 | -23.88% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $32.55 | +158.06% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $11.16 | +258.42% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $7.59 | +44.93% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $0.99 | +2,028.95% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $5.86 | +15,258.36% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.12
Upside: +2,132.14%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.73
Upside: +266.30%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $10.51
Upside: -23.88%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $32.55
Upside: +158.06%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $11.16
Upside: +258.42%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $7.59
Upside: +44.93%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $0.99
Upside: +2,028.95%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $5.86
Upside: +15,258.36%